Enveric Biosciences (NASDAQ:ENVB) Shares Down 6.3%

Enveric Biosciences, Inc. (NASDAQ:ENVB) traded down 6.3% on Thursday . The stock traded as low as $0.50 and last traded at $0.52. 216,288 shares traded hands during mid-day trading, an increase of 128% from the average session volume of 94,868 shares. The stock had previously closed at $0.55.

Enveric Biosciences Trading Down 6.3 %

The stock has a market capitalization of $4.01 million, a PE ratio of -0.08 and a beta of 0.74. The firm has a 50 day moving average of $0.77 and a two-hundred day moving average of $0.97.

Enveric Biosciences (NASDAQ:ENVB) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.61) earnings per share for the quarter, meeting the consensus estimate of ($0.61). Equities research analysts forecast that Enveric Biosciences, Inc. will post -1.98 EPS for the current year.

Hedge Funds Weigh In On Enveric Biosciences

A hedge fund recently bought a new stake in Enveric Biosciences stock. Virtu Financial LLC acquired a new position in shares of Enveric Biosciences, Inc. (NASDAQ:ENVB) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 33,835 shares of the company’s stock, valued at approximately $34,000. Virtu Financial LLC owned about 0.44% of Enveric Biosciences as of its most recent SEC filing. Hedge funds and other institutional investors own 13.82% of the company’s stock.

About Enveric Biosciences

Enveric Biosciences, Inc, a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.